{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:06:20Z","timestamp":1785305180125,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Statin has been more and more widely used in chronic liver disease, however, existed studies have attained contradictory results. According to the present study, we aimed to test the efficacy and safety of statin via a meta-analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Different databases were searched for full-text publication based on inclusion and exclusion criteria. For data-pooling, fixed-effect model was applied if heterogeneity wasn\u2019t detected. Otherwise, random-effect model was adopted. Heterogeneity was detected by I squire (<jats:italic>I<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>) test. All results of analysis were illustrated as forest plots. Publication bias was assessed using the Begg\u2019s adjusted rank correlation test. Standard mean difference (SMD) was calculated in continuous variables. Pooled hazard ratio or odds ratio was calculated in catergorical variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventeen clinical studies were finally included. Hepatic portal hemodynamic parameters were improved in statin users for a short-term response. For a long-term follow-up, statin treatment surprisingly decreased mortality rate (HR\u2009=\u20090.782, 95% CI: 0.718\u20130.846, <jats:italic>I<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u2009&gt;\u200950%) and lower the occurrence of hepatocellular carcinoma (HR\u2009=\u20090.75, 95% CI: 0.64\u20130.86, <jats:italic>I<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u2009&gt;\u200950%) in liver cirrhosis. Statin seemed not to decrease the risk of esophageal variceal bleeding and spontaneous bacterial peritonitis. However, statin was proved to decrease the risk of hepatic encephalopathy and ascites. Incidence of drug related adverse events didn\u2019t increase in statin users. Dose-dependent effects of statin on hepatocellular carcinoma development, decompensated cirrhosis events occurrence, and liver cirrhosis progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Statin influenced parameters of hepatic portal vessel pressure in short-term treatment. Prognosis of liver cirrhosis benefited from statin treatment in long term follow-up. The efficacy and safety of statin in liver cirrhosis treatment is confirmed. To date, similar study is hardly seen before.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-019-1147-1","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T15:02:37Z","timestamp":1577718157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Yue","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"issue":"9930","key":"1147_CR1","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","volume":"383","author":"EA Tsochatzis","year":"2014","unstructured":"Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet (London, England). 2014;383(9930):1749\u201361.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"1147_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D'Amico","year":"2006","unstructured":"D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217\u201331.","journal-title":"J Hepatol"},{"issue":"3","key":"1147_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","volume":"68","author":"G D'Amico","year":"2018","unstructured":"D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, et al. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68(3):563\u201376.","journal-title":"J Hepatol"},{"issue":"8","key":"1147_CR4","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1053\/j.gastro.2016.03.005","volume":"150","author":"Z Younossi","year":"2016","unstructured":"Younossi Z, Henry L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology. 2016;150(8):1778\u201385.","journal-title":"Gastroenterology."},{"issue":"9615","key":"1147_CR5","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","volume":"371","author":"D Schuppan","year":"2008","unstructured":"Schuppan D, Afdhal NH, et al. Lancet (London, England). 2008;371(9615):838\u201351.","journal-title":"Lancet (London, England)"},{"issue":"19","key":"1147_CR6","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.2015.15629","volume":"316","author":"R Chou","year":"2016","unstructured":"Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(19):2008\u201324.","journal-title":"JAMA."},{"issue":"1","key":"1147_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","volume":"120","author":"A Oesterle","year":"2017","unstructured":"Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229\u201343.","journal-title":"Circ Res"},{"issue":"6","key":"1147_CR8","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1002\/hep.28567","volume":"63","author":"JP Arab","year":"2016","unstructured":"Arab JP, Shah VH. Statins and portal hypertension: A tale of two models. Hepatology (Baltimore, Md). 2016;63(6):2044\u20137.","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"1147_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/SHK.0000000000000734","volume":"47","author":"CZ Meireles","year":"2017","unstructured":"Meireles CZ, Pasarin M, Lozano JJ, Garcia-Caldero H, Gracia-Sancho J, Garcia-Pagan JC, et al. Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage\/Resuscitation. Shock (Augusta, Ga). 2017;47(3):370\u20137.","journal-title":"Shock (Augusta, Ga)"},{"issue":"5","key":"1147_CR10","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1053\/j.gastro.2018.07.022","volume":"155","author":"DM Tripathi","year":"2018","unstructured":"Tripathi DM, Vilaseca M, Lafoz E, Garcia-Caldero H, Viegas Haute G, Fernandez-Iglesias A, et al. Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension. Gastroenterology. 2018;155(5):1564\u201377.","journal-title":"Gastroenterology."},{"issue":"9","key":"1147_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11894-017-0584-7","volume":"19","author":"JI Vargas","year":"2017","unstructured":"Vargas JI, Arrese M, Shah VH, Arab JP. Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects. Curr Gastroenterol Rep. 2017;19(9):43.","journal-title":"Curr Gastroenterol Rep"},{"issue":"10","key":"1147_CR12","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/ajg.2017.170","volume":"112","author":"S Kamal","year":"2017","unstructured":"Kamal S, Khan MA, Seth A, Cholankeril G, Gupta D, Singh U, et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic Decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis. Am J Gastroenterol. 2017;112(10):1495\u2013505.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"1147_CR13","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","volume":"15","author":"RG Kim","year":"2017","unstructured":"Kim RG, Loomba R, Prokop LJ, Singh S. Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521\u201330.e8.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1147_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","volume":"70","author":"E Pose","year":"2019","unstructured":"Pose E, Trebicka J, Mookerjee RP, Angeli P, Gines P. Statins: old drugs as new therapy for liver diseases? J Hepatol. 2019;70(1):194\u2013202.","journal-title":"J Hepatol"},{"issue":"4","key":"1147_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/cld.788","volume":"13","author":"C Kasia","year":"2019","unstructured":"Kasia C, Scaglione SJ. Patients with chronic liver disease\/cirrhosis should not take statin medications. Clin Liver Dis. 2019;13(4):106\u201310.","journal-title":"Clin Liver Dis"},{"issue":"1","key":"1147_CR16","doi-asserted-by":"publisher","first-page":"11674","DOI":"10.1038\/s41598-019-47943-6","volume":"9","author":"LW Unger","year":"2019","unstructured":"Unger LW, Forstner B, Schneglberger S, Muckenhuber M, Eigenbauer E, Bauer D, et al. Guideline-conform statin use reduces overall mortality in patients with compensated liver disease. Sci Rep. 2019;9(1):11674.","journal-title":"Sci Rep"},{"issue":"7","key":"1147_CR17","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/lt.25067","volume":"24","author":"SS Patel","year":"2018","unstructured":"Patel SS, Guzman LA, Lin FP, Pence T, Reichman T, John B, et al. Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation. Liver Transpl. 2018;24(7):872\u201380.","journal-title":"Liver Transpl"},{"key":"1147_CR18","doi-asserted-by":"publisher","first-page":"117955221878750","DOI":"10.1177\/1179552218787502","volume":"11","author":"MA Sigler","year":"2018","unstructured":"Sigler MA, Congdon L, Edwards KL. An evidence-based review of statin use in patients with nonalcoholic fatty liver disease. Clin Med Insights Gastroenterol. 2018;11:1179552218787502.","journal-title":"Clin Med Insights Gastroenterol"},{"issue":"4","key":"1147_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1136\/flgastro-2014-100500","volume":"6","author":"AP Wright","year":"2015","unstructured":"Wright AP, Adusumalli S, Corey KE. Statin therapy in patients with cirrhosis. Frontline Gastroenterol. 2015;6(4):255\u201361.","journal-title":"Frontline Gastroenterol"},{"key":"1147_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","volume":"88","author":"CR Sirtori","year":"2014","unstructured":"Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3\u201311.","journal-title":"Pharmacol Res"},{"issue":"5","key":"1147_CR21","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","volume":"136","author":"JG Abraldes","year":"2009","unstructured":"Abraldes JG, Albillos A, Banares R, Turnes J, Gonzalez R, Garcia-Pagan JC, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterol. 2009;136(5):1651\u20138.","journal-title":"Gastroenterol."},{"issue":"5","key":"1147_CR22","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","volume":"150","author":"JG Abraldes","year":"2016","unstructured":"Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, et al. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterol. 2016;150(5):1160\u201370.e3.","journal-title":"Gastroenterol"},{"issue":"7","key":"1147_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/apt.14243","volume":"46","author":"UC Bang","year":"2017","unstructured":"Bang UC, Benfield T, Bendtsen F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study. Aliment Pharmacol Ther. 2017;46(7):673\u201380.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1147_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","volume":"30","author":"S Bishnu","year":"2018","unstructured":"Bishnu S, Ahammed SM, Sarkar A, Hembram J, Chatterjee S, Das K, et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. Eur J Gastroenterol Hepatol. 2018;30(1):54\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"1147_CR25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/hep.29172","volume":"66","author":"FM Chang","year":"2017","unstructured":"Chang FM, Wang YP, Lang HC, Tsai CF, Hou MC, Lee FY, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study. Hepatology (Baltimore, Md). 2017;66(3):896\u2013907.","journal-title":"Hepatology (Baltimore, Md)"},{"key":"1147_CR26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.12688\/f1000research.13915.1","volume":"7","author":"N Elwan","year":"2018","unstructured":"Elwan N, Salah R, Hamisa M, Shady E, Hawash N, Abd-Elsalam S. Evaluation of portal pressure by doppler ultrasound in patients with cirrhosis before and after simvastatin administration - a randomized controlled trial. F1000Research. 2018;7:256.","journal-title":"F1000Research"},{"issue":"7","key":"1147_CR27","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/ajg.2016.179","volume":"111","author":"YW Huang","year":"2017","unstructured":"Huang YW, Lee CL, Yang SS, Fu SC, Chen YY, Wang TC, et al. Statins reduce the risk of cirrhosis and its Decompensation in chronic hepatitis B patients: a Nationwide cohort study. Am J Gastroenterol. 2017;111(7):976.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1147_CR28","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","volume":"156","author":"DE Kaplan","year":"2019","unstructured":"Kaplan DE, Serper MA, Mehta R, Fox R, John B, Aytaman A, et al. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology. 2019;156(6):1693\u2013706.e12.","journal-title":"Gastroenterology"},{"issue":"3","key":"1147_CR29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jhep.2017.10.018","volume":"68","author":"G Kim","year":"2018","unstructured":"Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested case-control study. J Hepatol. 2018;68(3):476\u201384.","journal-title":"J Hepatol"},{"issue":"8","key":"1147_CR30","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1007\/s10620-014-3179-2","volume":"59","author":"S Kumar","year":"2014","unstructured":"Kumar S, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci. 2014;59(8):1958\u201365.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"1147_CR31","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","volume":"150","author":"A Mohanty","year":"2016","unstructured":"Mohanty A, Tate JP, Garcia-Tsao G. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis. Gastroenterology. 2016;150(2):430\u201340.e1.","journal-title":"Gastroenterology"},{"issue":"11","key":"1147_CR32","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","volume":"47","author":"P Pollo-Flores","year":"2015","unstructured":"Pollo-Flores P, Soldan M, Santos UC, Kunz DG, Mattos DE, da Silva AC, et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig Liver Dis. 2015;47(11):957\u201363.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"1147_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/hep.28506","volume":"64","author":"TG Simon","year":"2016","unstructured":"Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology (Baltimore, Md). 2016;64(1):47\u201357.","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"1147_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jhep.2014.08.013","volume":"62","author":"TG Simon","year":"2015","unstructured":"Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol. 2015;62(1):18\u201323.","journal-title":"J Hepatol"},{"issue":"5","key":"1147_CR35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4254\/wjh.v9.i5.270","volume":"9","author":"ZA Wani","year":"2017","unstructured":"Wani ZA, Mohapatra S, Khan AA, Mohapatra A, Yatoo GN. Addition of simvastatin to carvedilol non responders: a new pharmacological therapy for treatment of portal hypertension. World J Hepatol. 2017;9(5):270\u20137.","journal-title":"World J Hepatol"},{"issue":"10","key":"1147_CR36","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/apt.14341","volume":"46","author":"JC Wong","year":"2017","unstructured":"Wong JC, Chan HL, Tse YK, Yip TC, Wong VW, Wong GL. Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. Aliment Pharmacol Ther. 2017;46(10):1001\u201310.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"1147_CR37","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jhep.2015.07.006","volume":"63","author":"YH Yang","year":"2015","unstructured":"Yang YH, Chen WC, Tsan YT, Chen MJ, Shih WT, Tsai YH, et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol. 2015;63(5):1111\u20137.","journal-title":"J Hepatol"},{"key":"1147_CR38","first-page":"g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clinical research ed). 2015;350:g7647.","journal-title":"BMJ (Clinical research ed)"},{"issue":"10170","key":"1147_CR39","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","volume":"393","author":"Cholesterol Treatment Trialists\u2019 Collaboration","year":"2019","unstructured":"Cholesterol Treatment Trialists\u2019 Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet (London, England). 2019;393(10170):407\u201315.","journal-title":"Lancet (London, England)"},{"issue":"7","key":"1147_CR40","doi-asserted-by":"publisher","first-page":"e030038","DOI":"10.1136\/bmjopen-2019-030038","volume":"9","author":"S Wan","year":"2019","unstructured":"Wan S, Huang C, Zhu X. Systematic review with a meta-analysis: clinical effects of statins on the reduction of portal hypertension and variceal haemorrhage in cirrhotic patients. BMJ Open. 2019;9(7):e030038.","journal-title":"BMJ Open"},{"issue":"50","key":"1147_CR41","doi-asserted-by":"publisher","first-page":"e13593","DOI":"10.1097\/MD.0000000000013593","volume":"97","author":"HD Choi","year":"2018","unstructured":"Choi HD, Chae SM. Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia: a systematic review and meta-analysis. Medicine. 2018;97(50):e13593.","journal-title":"Medicine."},{"issue":"8","key":"1147_CR42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.7326\/M18-0808","volume":"169","author":"Y He","year":"2018","unstructured":"He Y, Li X, Gasevic D, Brunt E, McLachlan F, Millenson M, et al. Statins and multiple noncardiovascular outcomes: umbrella review of meta-analyses of observational studies and randomized controlled trials. Ann Intern Med. 2018;169(8):543\u201353.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1147_CR43","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.clinre.2017.07.004","volume":"41","author":"X Ma","year":"2017","unstructured":"Ma X, Sun D, Li C, Ying J, Yan Y. Statin use and virus-related cirrhosis: a systemic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(5):533\u201342.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"1147_CR44","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","volume":"6","author":"H Naci","year":"2013","unstructured":"Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6(4):390\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"8","key":"1147_CR45","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/liv.13371","volume":"37","author":"A Ascione","year":"2017","unstructured":"Ascione A, Fontanella L, Imparato M, Rinaldi L, De Luca M. Mortality from cirrhosis and hepatocellular carcinoma in Western Europe over the last 40 years. Liver Int. 2017;37(8):1193\u2013201.","journal-title":"Liver Int"},{"issue":"9399","key":"1147_CR46","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet (London, England). 2003;362(9399):1907\u201317.","journal-title":"Lancet (London, England)"},{"issue":"20","key":"1147_CR47","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","volume":"67","author":"PD Thompson","year":"2016","unstructured":"Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395\u2013410.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1147_CR48","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.jacl.2016.09.004","volume":"10","author":"O Baspinar","year":"2016","unstructured":"Baspinar O, Bayram F, Korkmaz S, Aksu M, Kocer D, Dizdar OS, et al. The effects of statin treatment on adrenal and sexual function and nitric oxide levels in hypercholesterolemic male patients treated with a statin. J Clin Lipidol. 2016;10(6):1452\u201361.","journal-title":"J Clin Lipidol"},{"issue":"7","key":"1147_CR49","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","volume":"33","author":"U Forstermann","year":"2012","unstructured":"Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33(7):829\u201337 37a-37d.","journal-title":"Eur Heart J"},{"issue":"3","key":"1147_CR50","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/hep.26127","volume":"57","author":"LM Vincenzo","year":"2013","unstructured":"Vincenzo LM, Marcos P, Meireles CZ, Rosa M, Aina RV, Diana H, et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology (Baltimore, Md). 2013;57(3):1172\u201381.","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"1147_CR51","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S1734-1140(10)70274-7","volume":"62","author":"M Trocha","year":"2010","unstructured":"Trocha M, Merwid-Lad A, Szuba A, Chlebda E, Piesniewska M, Sozanski T, et al. Effect of simvastatin on nitric oxide synthases (eNOS, iNOS) and arginine and its derivatives (ADMA, SDMA) in ischemia\/reperfusion injury in rat liver. Pharmacol Rep. 2010;62(2):343\u201351.","journal-title":"Pharmacol Rep"},{"issue":"3","key":"1147_CR52","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","volume":"126","author":"C Zafra","year":"2004","unstructured":"Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernandez M, Garca-Pagan JC, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126(3):749\u201355.","journal-title":"Gastroenterology."},{"issue":"1","key":"1147_CR53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.repc.2015.09.006","volume":"35","author":"S Costa","year":"2016","unstructured":"Costa S, Reina-Couto M, Albino-Teixeira A, Sousa T. Statins and oxidative stress in chronic heart failure. Rev Port Cardiol. 2016;35(1):41\u201357.","journal-title":"Rev Port Cardiol"},{"issue":"1","key":"1147_CR54","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s12035-014-9030-0","volume":"53","author":"SH Lee","year":"2016","unstructured":"Lee SH, Choi NY, Yu HJ, Park J, Choi H, Lee KY, et al. Atorvastatin protects NSC-34 motor neurons against oxidative stress by activating PI3K, ERK and free radical scavenging. Mol Neurobiol. 2016;53(1):695\u2013705.","journal-title":"Mol Neurobiol"},{"key":"1147_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","volume":"71","author":"VG Athyros","year":"2017","unstructured":"Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metab Clin Exp. 2017;71:17\u201332.","journal-title":"Metab Clin Exp"},{"issue":"5","key":"1147_CR56","doi-asserted-by":"publisher","first-page":"G407","DOI":"10.1152\/ajpgi.00441.2016","volume":"312","author":"R Schierwagen","year":"2017","unstructured":"Schierwagen R, Uschner FE, Magdaleno F, Klein S, Trebicka J. Rationale for the use of statins in liver disease. Am J Physiol Gastrointest Liver Physiol. 2017;312(5):G407\u2013g12.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"1147_CR57","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12944-017-0572-9","volume":"16","author":"Z Chen","year":"2017","unstructured":"Chen Z, Yu R, Xiong Y, Du F, Zhu S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16(1):203.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"1147_CR58","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/hep.24394","volume":"54","author":"L Franceschini","year":"2011","unstructured":"Franceschini L, Realdon S, Marcolongo M, Mirandola S, Bortoletto G, Alberti A. Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: a vicious circle of clinical significance? Hepatology (Baltimore, Md). 2011;54(2):484\u201394.","journal-title":"Hepatology (Baltimore, Md)"},{"key":"1147_CR59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12876-015-0311-5","volume":"15","author":"TY Zhao","year":"2015","unstructured":"Zhao TY, Su LP, Ma CY, Zhai XH, Duan ZJ, Zhu Y, et al. IGF-1 decreases portal vein endotoxin via regulating intestinal tight junctions and plays a role in attenuating portal hypertension of cirrhotic rats. BMC Gastroenterol. 2015;15:77.","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"1147_CR60","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","volume":"127","author":"G Fattovich","year":"2004","unstructured":"Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5):S35\u201350.","journal-title":"Gastroenterology."},{"key":"1147_CR61","first-page":"3361","volume":"9","author":"O Barbarash","year":"2015","unstructured":"Barbarash O, Gruzdeva O, Uchasova E, Belik E, Dyleva Y, Karetnikova V. Dose-dependent effects of atorvastatin on myocardial infarction. Drug Des Devel Ther. 2015;9:3361\u20138.","journal-title":"Drug Des Devel Ther"},{"key":"1147_CR62","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ijcard.2015.02.072","volume":"184","author":"M Henein","year":"2015","unstructured":"Henein M, Granasen G, Wiklund U, Schmermund A, Guerci A, Erbel R, et al. High dose and long-term statin therapy accelerate coronary artery calcification. Int J Cardiol. 2015;184:581\u20136.","journal-title":"Int J Cardiol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1147-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-019-1147-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1147-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:28:06Z","timestamp":1609201686000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-019-1147-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1147"],"URL":"https:\/\/doi.org\/10.1186\/s12876-019-1147-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"19 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a meta-analysis. So the ethics approval is not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}